Alzheimer’s Disease
Denali is committed to working towards the discovery of potential treatments for Alzheimer’s disease, a progressive neurodegenerative disorder.
Currently Denali’s pipeline has several possible future treatments that are targeting various potential causes of Alzheimer’s disease. These drugs are currently at the discovery stage.
“We’re very clear on what the mission is: to improve patients’ lives and get these therapies to patients. Patients are always at the forefront here, whether it’s our connection to patient communities, or our patient fellows at the company, and overall continuing to connect the science back to the patients.”
Cathal Mahon - Director and Principal Scientist, Denali Therapeutics
For questions, please contact the Denali Patient Advocacy team at patients@dnli.com.